BioSpace News Archive

Syndax Pharmaceuticals announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 4:45 p.m. ET.

Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.

Stoke Therapeutics, Inc. reported financial results for the third quarter of 2023 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced that the Company will present at the following investor conferences.

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023.

Minerva Neurosciences, Inc. reported business updates and financial results for the third quarter ended September 30, 2023.

Dyne Therapeutics, Inc today announced that management is scheduled to present at the following investor conferences in November.

Repligen Corporation today announced that it will be presenting at two upcoming investor conferences.

Adaptive Biotechnologies Corporation today announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies.

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today reported third quarter 2023 financial results and provided a corporate update.